
    
      This study is a dose Block-randomized, Double-blind, Placebo-controlled and Dose-escalation
      Phase I Clinical Trial to Evaluate Safety of BLS-M22.

      The single ascending dose group participated in 9 patients in each group(500mg, 1,000mg,
      2000mg/BLS-M22 or Placebo(n=7:2)). The multiple ascending dose group participated in 10
      patients(determined dose in SAD/BLS-M22 or Placebo(n=8:2)).
    
  